| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1352458512464686 |
| P698 | PubMed publication ID | 23124791 |
| P50 | author | Antonio Uccelli | Q57007173 |
| Alice Laroni | Q59660043 | ||
| P2093 | author name string | Mark S Freedman | |
| P2860 | cites work | Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery | Q44115092 |
| Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice | Q46499204 | ||
| Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. | Q46670167 | ||
| Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. | Q47894301 | ||
| Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis | Q48227850 | ||
| Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study | Q48321211 | ||
| Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis | Q48332405 | ||
| Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice | Q48497239 | ||
| Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. | Q50632074 | ||
| Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. | Q50767537 | ||
| Inflammatory Cytokine Induced Regulation of Superoxide Dismutase 3 Expression by Human Mesenchymal Stem Cells | Q54416919 | ||
| Sudden unexpected death on fingolimod. | Q55055635 | ||
| Bone marrow cells regenerate infarcted myocardium | Q28210640 | ||
| Mesenchymal stem cells in health and disease | Q29614296 | ||
| Mesenchymal and haematopoietic stem cells form a unique bone marrow niche | Q29616602 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
| Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta | Q33855709 | ||
| Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis | Q34120467 | ||
| Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study | Q34132522 | ||
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
| Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis | Q34564111 | ||
| Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains | Q35630632 | ||
| Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study | Q35757641 | ||
| Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. | Q36188460 | ||
| Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. | Q37253314 | ||
| Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis | Q37484571 | ||
| The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group | Q37677911 | ||
| Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? | Q37811173 | ||
| Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases | Q37891375 | ||
| Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence | Q37976344 | ||
| The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms | Q37978701 | ||
| Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo | Q40662801 | ||
| Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis | Q43831215 | ||
| P433 | issue | 5 | |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| P304 | page(s) | 515-519 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Multiple Sclerosis Journal | Q1952449 |
| P1476 | title | Mesenchymal stem cells as treatment for MS - progress to date | |
| P478 | volume | 19 |
| Q42511103 | Adipose tissue-derived stromal cells (ADSC) express oligodendrocyte and myelin markers, but they do not function as oligodendrocytes |
| Q37202733 | Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model |
| Q37637831 | Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function |
| Q33757255 | Are nestin-positive mesenchymal stromal cells a better source of cells for CNS repair? |
| Q54565698 | Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. |
| Q34961598 | Bone marrow stromal cells as immunomodulators. A primer for dermatologists |
| Q49541054 | CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases. |
| Q64966459 | Comparison of the effects of 17β- estradiol treated and untreated mesenchymal stem cells on ameliorating animal model of multiple sclerosis. |
| Q33750137 | Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme |
| Q38142030 | Disease-modifying treatments for progressive multiple sclerosis |
| Q93136005 | Human ES-derived MSCs correct TNF-α-mediated alterations in a blood-brain barrier model |
| Q28081780 | Induced Stem Cells as a Novel Multiple Sclerosis Therapy |
| Q36071006 | Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. |
| Q43242462 | Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats |
| Q64061462 | MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis |
| Q42327942 | MSC Therapeutics in Chronic Inflammation |
| Q35654025 | Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing-remitting multiple sclerosis model. |
| Q35213818 | Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE) |
| Q30690412 | Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. |
| Q40198530 | Molecular Mechanisms Mediating Retinal Reactive Gliosis Following Bone Marrow Mesenchymal Stem Cell Transplantation. |
| Q46944384 | Nicotine Augments the Beneficial Effects of Mesenchymal Stem Cell-based Therapy in Rat Model of Multiple Sclerosis. |
| Q37199722 | Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells |
| Q34419649 | Primary mesenchymal stem cells in human transplanted lungs are CD90/CD105 perivascularly located tissue-resident cells |
| Q47363542 | Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro |
| Q49343380 | Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis |
| Q36700629 | Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem cells during experimental autoimmune encephalomyelitis |
| Q42746891 | Sphingosine 1-Phosphate Receptor 2 Regulates the Migration, Proliferation, and Differentiation of Mesenchymal Stem Cells |
| Q26750597 | The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies |
| Q38098448 | Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system |
| Q37499253 | Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis model |
| Q88040135 | [Mesenchymal stem/stroma cells : Therapeutic potential in the treatment of autoimmune diseases] |
Search more.